ArticleOncotarget2017

Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.

Satoshi Fujii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.